<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00151775</url>
  </required_header>
  <id_info>
    <org_study_id>CS0866-A-U301</org_study_id>
    <nct_id>NCT00151775</nct_id>
  </id_info>
  <brief_title>Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure</brief_title>
  <official_title>Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16
      with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks
      participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, multicenter, double-blind, parallel-group, prospective dose-ranging
      study in subjects 1 to 16 years of age with hypertension. Subjects were enrolled into 1 of 3
      cohorts based on age and race. Subjects 6 to 16 years of age were enrolled into Cohort A.
      Subjects enrolled into Cohort A were stratified by age with approximately half aged 6 to 12
      years and the remainder aged 13 to 16 years. Approximately 15% of the subjects in Cohort A
      were to be Black or of African descent. When a minimum of 28 Black subjects were randomized
      into Cohort A, enrollment in Cohort B was started. Black subjects only, 6 to 16 years of age,
      were enrolled into Cohort B. For Cohorts A and B body weight of any patient was &gt;=20Kg.
      Seated systolic blood pressure (SeSBP) was &gt;=95th percentile for gender and height-for-age,
      or &gt;=90th percentile if the patient is diabetic, or has glomerular kidney disease, or has a
      family history of hypertension. Patients with symptomatic hypertension requiring immediate
      established therapy, or who are above 2 standard deviations (SD) above the 99th percentile
      did not participate in the study.

      Subjects 1 to 5 years of age were enrolled into Cohort C regardless of race. Body weight of
      any patient was &gt;=5Kg. SeSBP was &gt;=95th percentile for gender and height-for-age, or &gt;=90th
      percentile if the patient is diabetic, or has glomerular kidney disease, or has a family
      history of hypertension. Patients on stable doses of concomitant antihypertensive agents
      including calcium channel blockers and/or diuretics only are permitted to enroll. Patients
      with symptomatic hypertension requiring immediate established therapy, or who are above 2 SD
      above the 99th percentile did not participate in the study.

      The study comprised four periods. Period I was a wash-out period from Week -1 to
      randomization. Subjects were randomized to treatment sequences carried through the remainder
      of the study. Period II was a three-week, double-blind, dose-ranging period for Cohorts A and
      B, beginning at Day 1 and ending at the end of Week 3. In Cohorts A and B, subjects received
      either low-dose or high-dose olmesartan (OM) once daily. In Cohort C, Period II was an
      open-label OM treatment period where all subjects received 0.3 mg/kg OM per day. Period III
      was a double-blind, placebo-controlled withdrawal period beginning at Week 4 and ending after
      1 or 2 weeks, depending on the seated blood pressure measurement at each weekly study visit.
      Subjects either continued their Period II OM regimen or switched to placebo based on the
      initial randomization scheme. Period IV was a 46-week open-label extension period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)</measure>
    <time_frame>Day 0 to 3 weeks</time_frame>
    <description>The efficacy dose response change in trough seated systolic blood pressure (both non-weight adjusted and weight adjusted results) from baseline to the end of the dose-ranging period (Period 2). Non-weight adjusted dose was the fixed olmesartan medoxomil dose; weight adjusted dose calculated mg of olmesartan medoxomil per kg of weight at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks)</measure>
    <time_frame>Day 0 (baseline) to 3 weeks</time_frame>
    <description>Mean change from baseline to the end of the dose ranging period in systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3</measure>
    <time_frame>Week 3 (period 3 baseline) to week 5 (end of Period 3)</time_frame>
    <description>Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3</measure>
    <time_frame>Week 3 (period 3 baseline) to week 5 (end of Period 3)</time_frame>
    <description>Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)</measure>
    <time_frame>Day 0 to week 51 (end of study)</time_frame>
    <description>Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)</measure>
    <time_frame>Day 0 to week 51 week (end of study)</time_frame>
    <description>Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort C.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For Cohorts A and B, olmesartan medoxomil suspension 2.5 mg to 40 mg in patients 6-16 years old, depending on weight.
For Cohort C, olmesartan medoxomil suspension 0.3 mg/kg to in patients 1-5 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts A, B, C - olmesartan medoxomil suspension or placebo taken once daily. Olmesartan medoxomil dose continued as in previous period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg
Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.
Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily</description>
    <arm_group_label>Period 2</arm_group_label>
    <arm_group_label>Period 3</arm_group_label>
    <other_name>Benicar (olmesartan medoxomil)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Cohorts A, B, C: placebo, once daily</description>
    <arm_group_label>Period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.
Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg</description>
    <arm_group_label>Period 4</arm_group_label>
    <other_name>Benicar (olmesartan medoxomil)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient's seated systolic BP (SeSBP) will be greater than or equal to 95th
             percentile for gender and height-for- age, or greater than or equal to 90th percentile
             if the patient is diabetic, or has glomerular kidney disease, or has a family history
             of hypertension.

          -  Negative for hepatitis B and C

          -  Negative for HIV

        Exclusion Criteria:

          -  Patient should not have serious other conditions that could interfere with the
             analysis of the results or that could interfere with the well-being of the patient in
             the trial.

          -  Known sensitivity to olmesartan medoxomil

          -  Taking prohibited medication

          -  Consumed greater than 180 mg of caffeine daily

          -  Malignant hypertension

          -  History of congestive heart failure, cardiomyopathy, or obstructive valve disease

          -  Renal transplant within the previous 6 months

          -  Severe nephritic syndrome not in remission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>TUC</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bahia Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali-Valle</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mangalore</city>
        <state>Karna</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vellore</city>
        <state>Karna</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucknow</city>
        <state>Uttar Prad</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandigarh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <zip>500 033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <zip>110 029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <zip>7764</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban, KZ-Natal</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>E Cape</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eastern Cape</city>
        <zip>5200</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Park Town, Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pietermaritzburg, KZ-Natal</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Potchefstroom, NW</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria, Gauteng</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Western Cape</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitwe</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>India</country>
    <country>Kenya</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>United States</country>
    <country>Zambia</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <results_first_submitted>March 8, 2010</results_first_submitted>
  <results_first_submitted_qc>March 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 2, 2010</results_first_posted>
  <disposition_first_submitted>August 19, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>August 19, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 21, 2009</disposition_first_posted>
  <last_update_submitted>May 26, 2016</last_update_submitted>
  <last_update_submitted_qc>May 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of hypertension or high blood pressure in children ages 1-16 years.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Period 1 was a screening, wash-out period of approximately two weeks. All participants were included in the screening, wash-out period and during this period no intervention was administered.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort A: High Dose OM in Periods 2, 3</title>
          <description>Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given a high dose (20 mg or 40 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period from day 0 to week 3). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period from week 3 to week 5).</description>
        </group>
        <group group_id="P2">
          <title>Cohort A: Low Dose OM in Periods 2, 3</title>
          <description>Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given a low dose (2.5 mg or 5.0 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period from day 0 to week 3). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period from week 3 to week 5).</description>
        </group>
        <group group_id="P3">
          <title>Cohort A: Placebo in Period 3 (From High Dose in Period 2)</title>
          <description>Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5) instead of the previous high dose of olmesartan</description>
        </group>
        <group group_id="P4">
          <title>Cohort A: Placebo in Period 3 (From Low Dose in Period 2)</title>
          <description>Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5) instead of the previous low dose of olmesartan.</description>
        </group>
        <group group_id="P5">
          <title>Cohort A: Period 4 Open-label OM</title>
          <description>All members of Cohort A (6-16 years old with a limit on the number of Black participants) were given 10 mg to 40 mg of olmesartan (OM) administered as oral suspension or tablets depending on participant weight and response in the open-label Period 4 (weeks 6-51). Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
        </group>
        <group group_id="P6">
          <title>Cohort B: High Dose OM in Periods 2, 3</title>
          <description>Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given a high dose (20 mg or 40 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period from day 0 to week 3). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period from week 3 to week 5).</description>
        </group>
        <group group_id="P7">
          <title>Cohort B: Low Dose OM in Periods 2, 3</title>
          <description>Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given a low dose (2.5 mg or 5.0 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period from day 0 to week 3). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period from week 3 to week 5).</description>
        </group>
        <group group_id="P8">
          <title>Cohort B: Placebo in Period 3 (From High Dose in Period 2)</title>
          <description>Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5) instead of the previous high dose of olmesartan.</description>
        </group>
        <group group_id="P9">
          <title>Cohort B: Placebo in Period 3 (From Low Dose in Period 2)</title>
          <description>Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5) instead of the previous low dose of olmesartan.</description>
        </group>
        <group group_id="P10">
          <title>Cohort B: Period 4 Open-label OM</title>
          <description>All members of Cohort B (6-16 years old comprised exclusively of Black participants) were given 10 mg to 40 mg of olmesartan (OM) administered as oral suspension or tablets depending on participant weight and response in the open-label Period 4 (weeks 6-51). Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
        </group>
        <group group_id="P11">
          <title>Cohort C: OM in Periods 2, 3, 4</title>
          <description>Cohort C (1-5 years old) was given olmesartan medoxomil (OM) 0.3 mg/kg in Period 2 (open-label period from day 0 to week 3) and a subgroup of Cohort C was given that dose of OM during Period 3 (double-blind, placebo-controlled period from week 3 to week 5). In Period 4 (open-label period from weeks 6-51), all of Cohort C received an OM starting dose of 0.3 mg/kg. If hypertension was not controlled after two week the dose was doubled. Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
        </group>
        <group group_id="P12">
          <title>Cohort C: Placebo in Period 3 (From OM in Period 2)</title>
          <description>Subgroup of Cohort C (1-5 years old) given placebo during Period 3 (double-blind, placebo-controlled period from week 3 to week 5).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 2 - Double-Blind Dose Response</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="56"/>
                <participants group_id="P7" count="56"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="60"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="53"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="59"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>The blood pressure goal was met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3: Double-blind, Withdrawal</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="27"/>
                <participants group_id="P8" count="28"/>
                <participants group_id="P9" count="26"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="29"/>
                <participants group_id="P12" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="26"/>
                <participants group_id="P8" count="27"/>
                <participants group_id="P9" count="26"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="29"/>
                <participants group_id="P12" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met blood pressure goal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4: Open Label</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="179"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="104"/>
                <participants group_id="P11" count="57"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="149"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="83"/>
                <participants group_id="P11" count="57"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="21"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Increased blood pressure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A: High Dose OM</title>
          <description>Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given a high dose (20 mg or 40 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period).</description>
        </group>
        <group group_id="B2">
          <title>Cohort A: Low Dose OM</title>
          <description>Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given a low dose (2.5 mg or 5.0 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period).</description>
        </group>
        <group group_id="B3">
          <title>Cohort B: High Dose OM</title>
          <description>Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given a high dose (20 mg or 40 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period).</description>
        </group>
        <group group_id="B4">
          <title>Cohort B: Low Dose OM</title>
          <description>Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given a low dose (2.5 mg or 5.0 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period).</description>
        </group>
        <group group_id="B5">
          <title>Cohort C: OM (Olmesartan Medoxomil)</title>
          <description>Cohort C (1-5 years old) was given olmesartan medoxomil (OM) 0.3 mg/kg in Period 2 (open-label period) and a subgroup of Cohort C was given that dose of OM during Period 3 (double-blind, placebo-controlled period). In Period 4 (open-label period), all of Cohort C received an OM starting dose of 0.3 mg/kg. If hypertension was not controlled after two week the dose was doubled. Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="56"/>
            <count group_id="B5" value="60"/>
            <count group_id="B6" value="362"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The data provided for the total study population includes only Cohorts A+B.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.1" spread="2.97"/>
                    <measurement group_id="B2" value="12.3" spread="2.98"/>
                    <measurement group_id="B3" value="12.2" spread="2.83"/>
                    <measurement group_id="B4" value="12.8" spread="2.42"/>
                    <measurement group_id="B5" value="3.4" spread="1.45"/>
                    <measurement group_id="B6" value="12.3" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Latino/Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-Latino/Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>The data provided for the total study population is only for Cohorts A+B</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153.3" spread="18.46"/>
                    <measurement group_id="B2" value="155.1" spread="19.12"/>
                    <measurement group_id="B3" value="154.2" spread="17.83"/>
                    <measurement group_id="B4" value="156.1" spread="14.21"/>
                    <measurement group_id="B5" value="98.3" spread="12.92"/>
                    <measurement group_id="B6" value="154.6" spread="17.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Seated Systolic blood pressure</title>
          <description>The data provided for the total study population is only for Cohort A+B</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129.1" spread="8.32"/>
                    <measurement group_id="B2" value="129.5" spread="9.10"/>
                    <measurement group_id="B3" value="130.8" spread="9.73"/>
                    <measurement group_id="B4" value="131.7" spread="9.12"/>
                    <measurement group_id="B5" value="115.2" spread="8.74"/>
                    <measurement group_id="B6" value="130.0" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Seated diastolic blood pressure</title>
          <description>The data provided for the total study population consists only of Cohort A+B</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.3" spread="8.09"/>
                    <measurement group_id="B2" value="78.1" spread="8.17"/>
                    <measurement group_id="B3" value="79.2" spread="7.08"/>
                    <measurement group_id="B4" value="79.4" spread="9.05"/>
                    <measurement group_id="B5" value="72.7" spread="8.74"/>
                    <measurement group_id="B6" value="78.0" spread="8.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>The data provided for the total study population is only for Cohort A+B</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" spread="34.22"/>
                    <measurement group_id="B2" value="78.9" spread="41.85"/>
                    <measurement group_id="B3" value="66.2" spread="32.39"/>
                    <measurement group_id="B4" value="68.1" spread="34.36"/>
                    <measurement group_id="B5" value="16.9" spread="6.61"/>
                    <measurement group_id="B6" value="71.1" spread="36.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)</title>
        <description>The efficacy dose response change in trough seated systolic blood pressure (both non-weight adjusted and weight adjusted results) from baseline to the end of the dose-ranging period (Period 2). Non-weight adjusted dose was the fixed olmesartan medoxomil dose; weight adjusted dose calculated mg of olmesartan medoxomil per kg of weight at baseline.</description>
        <time_frame>Day 0 to 3 weeks</time_frame>
        <population>The number of participants includes all randomized to Cohort A, Cohort B and a combination of the two cohorts. The Last Observation Carried Forward method was used in the linear regression analysis for the change in the seated systolic blood pressure from baseline to the end of three weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A</title>
            <description>Cohort A participants were 6-16 years old with a limit on the number of Black participants. Includes participants randomized to both the high dose of olmesartan medoxomil suspension (20 mg or 40 mg) and the low dose (2.5 mg or 5.0mg), depending on weight, administered once daily.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B</title>
            <description>Cohort B participants were 6-16 years old and comprised exclusively of Black participants. Includes participants randomized to both the high dose of olmesartan medoxomil suspension (20 mg or 40 mg) and the low dose (2.5 mg or 5.0 mg), depending on weight, administered once daily.</description>
          </group>
          <group group_id="O3">
            <title>Cohorts A + B</title>
            <description>Cohort A + B participants were 6-16 years old. Cohort A limited the number of Black participants, while Cohort B was comprised exclusively of Black participants. Includes participants randomized to both the high dose of olmesartan medoxomil suspension (20 mg or 40 mg) and the low dose (2.5 mg or 5.0mg), depending on weight, administered once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)</title>
          <description>The efficacy dose response change in trough seated systolic blood pressure (both non-weight adjusted and weight adjusted results) from baseline to the end of the dose-ranging period (Period 2). Non-weight adjusted dose was the fixed olmesartan medoxomil dose; weight adjusted dose calculated mg of olmesartan medoxomil per kg of weight at baseline.</description>
          <population>The number of participants includes all randomized to Cohort A, Cohort B and a combination of the two cohorts. The Last Observation Carried Forward method was used in the linear regression analysis for the change in the seated systolic blood pressure from baseline to the end of three weeks.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-weight adjusted dosage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.202"/>
                    <measurement group_id="O2" value="-0.85" spread="0.282"/>
                    <measurement group_id="O3" value="-0.75" spread="0.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight adjusted dosage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.97" spread="2.054"/>
                    <measurement group_id="O2" value="-7.17" spread="3.190"/>
                    <measurement group_id="O3" value="-8.36" spread="1.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Non-weight adjusted dosage</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Weight adjusted dosage</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-weight adjusted dosage</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Weight adjusted dosage</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0265</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-weight adjusted dosage</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Weight adjusted dosage</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks)</title>
        <description>Mean change from baseline to the end of the dose ranging period in systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.</description>
        <time_frame>Day 0 (baseline) to 3 weeks</time_frame>
        <population>The Intent-to-Treat (ITT) population for Period II of the study was defined as subjects who took at least one dose of study medication and had study baseline and at least one seated systolic, or diastolic blood pressure measurement after taking study medication. The Last Observation carried forward was used</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Low Dose OM</title>
            <description>Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given a low dose (2.5 mg or 5.0 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period).</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: High Dose OM</title>
            <description>Subgroup of Cohort A (6-16 years old with a limit on the number of Black participants) given a high dose (20 mg or 40 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period).</description>
          </group>
          <group group_id="O3">
            <title>Cohort B: Low Dose OM</title>
            <description>Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given a low dose (2.5 mg or 5.0 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period).</description>
          </group>
          <group group_id="O4">
            <title>Cohort B: High Dose OM</title>
            <description>Subgroup of Cohort B (6-16 years old comprised exclusively of Black participants) given a high dose (20 mg or 40 mg) of olmesartan medoxomil suspension (OM) depending on weight during Period 2 (double-blind, dose-response period). Half of the participants continued this dose into Period 3 (double-blind, placebo controlled period).</description>
          </group>
          <group group_id="O5">
            <title>Cohorts A + B: Low Dose OM</title>
            <description>Subgroup from Cohorts A + B (6-16 years old) who received the low dose of olmesartan medoxomil suspension (OM 2.5 mg or 5.0 mg depending on weight), administered once daily in Period 2. Cohort A limited the number of Black participants, while Cohort B was comprised exclusively of Black participants.</description>
          </group>
          <group group_id="O6">
            <title>Cohorts A + B: High Dose OM</title>
            <description>Subgroup from Cohorts A + B (6-16 years old) who received the high dose of olmesartan medoxomil suspension (OM 20 mg or 40 mg depending on weight), administered once daily in Period 2. Cohort A limited the number of Black participants, while Cohort B was comprised exclusively of Black participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks)</title>
          <description>Mean change from baseline to the end of the dose ranging period in systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.</description>
          <population>The Intent-to-Treat (ITT) population for Period II of the study was defined as subjects who took at least one dose of study medication and had study baseline and at least one seated systolic, or diastolic blood pressure measurement after taking study medication. The Last Observation carried forward was used</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="150"/>
                <count group_id="O6" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.76" spread="9.180"/>
                    <measurement group_id="O2" value="-12.58" spread="10.157"/>
                    <measurement group_id="O3" value="-4.73" spread="11.483"/>
                    <measurement group_id="O4" value="-10.68" spread="9.259"/>
                    <measurement group_id="O5" value="-6.63" spread="10.170"/>
                    <measurement group_id="O6" value="-11.87" spread="9.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.52" spread="8.058"/>
                    <measurement group_id="O2" value="-9.50" spread="9.757"/>
                    <measurement group_id="O3" value="-3.49" spread="8.844"/>
                    <measurement group_id="O4" value="-7.58" spread="8.172"/>
                    <measurement group_id="O5" value="-4.76" spread="8.389"/>
                    <measurement group_id="O6" value="-8.78" spread="9.216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (non-weight adjusted) on the change from baseline in seated systolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (non-weight adjusted) on the change from baseline in seated diastolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-.057</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (non-weight adjusted) on the change from baseline in seated systolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.85</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (non-weight adjusted) on the change from baseline in seated diastolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.58</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (non-weight adjusted) on the change from baseline in seated systolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (non-weight adjusted) on the change from baseline in seated diastolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (weight adjusted) on the change from baseline in seated systolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-8.97</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (weight adjusted) on the change from baseline in seated diastolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-8.15</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (weight adjusted) on the change from baseline in seated systolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0265</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-7.17</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (weight adjusted) on the change from baseline in seated diastolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0084</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-6.85</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (weight adjusted) on the change from baseline in seated systolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-8.36</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>A linear regression analysis of olmesartan dose (weight adjusted) on the change from baseline in seated diastolic blood pressure was carried out. The null hypothesis of zero-slope was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Linear</method>
            <param_type>Slope</param_type>
            <param_value>-7.71</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3</title>
        <description>Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.</description>
        <time_frame>Week 3 (period 3 baseline) to week 5 (end of Period 3)</time_frame>
        <population>Intent to treat population defined as subjects who finished Period 2, had the end of Period 2 seated systolic or diastolic blood pressure measurement, took the Period 3 study medication for at least one week, and had the end of Period 3 seated systolic or diastolic blood pressure measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: OM Period 3</title>
            <description>Cohort A participants were 6-16 years old with a limit on the number of Black participants. Includes participants randomized to both the high dose of olmesartan medoxomil suspension (OM 20 mg or 40 mg) and the low dose (2.5 mg or 5.0mg), depending on weight, administered once daily in period 2, and continued that dosage into period 3.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Placebo Period 3</title>
            <description>Cohort A participants were 6-16 years old with a limit on the number of Black participants. Includes participants randomized to both the high and low dose of olmesartan medoxomil suspension in period 2, and changed to placebo in period 3.</description>
          </group>
          <group group_id="O3">
            <title>Cohort B: OM Period 3</title>
            <description>Cohort B participants were 6-16 years old and comprised exclusively of Black participants. Includes participants randomized to both the high dose of olmesartan medoxomil suspension (OM 20 mg or 40 mg) and the low dose (2.5 mg or 5.0mg), depending on weight, administered once daily in period 2, and continued that dosage into period 3.</description>
          </group>
          <group group_id="O4">
            <title>Cohort B: Placebo Period 3</title>
            <description>Cohort B participants were 6-16 years old and comprised exclusively of Black participants. Includes participants randomized to both the high and low dose of olmesartan medoxomil suspension in period 2, and changed to placebo in period 3.</description>
          </group>
          <group group_id="O5">
            <title>Cohorts A + B: OM Period 3</title>
            <description>Cohort A + B participants were 6-16 years old. Includes participants randomized to both the high dose of olmesartan medoxomil suspension (OM 20 mg or 40 mg) and the low dose (2.5 mg or 5.0mg), depending on weight, administered once daily in period 2, and continued that dosage into period 3.</description>
          </group>
          <group group_id="O6">
            <title>Cohorts A + B: Placebo Period 3</title>
            <description>Cohorts A + B participants were 6-16 years old. Includes participants randomized to both the high and low dose of olmesartan medoxomil suspension in period 2, and changed to placebo in period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3</title>
          <description>Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.</description>
          <population>Intent to treat population defined as subjects who finished Period 2, had the end of Period 2 seated systolic or diastolic blood pressure measurement, took the Period 3 study medication for at least one week, and had the end of Period 3 seated systolic or diastolic blood pressure measurement.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="54"/>
                <count group_id="O5" value="146"/>
                <count group_id="O6" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="9.46"/>
                    <measurement group_id="O2" value="4.93" spread="9.62"/>
                    <measurement group_id="O3" value="1.37" spread="9.50"/>
                    <measurement group_id="O4" value="3.79" spread="10.00"/>
                    <measurement group_id="O5" value="0.77" spread="9.451"/>
                    <measurement group_id="O6" value="4.50" spread="9.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="8.12"/>
                    <measurement group_id="O2" value="4.43" spread="10.15"/>
                    <measurement group_id="O3" value="1.94" spread="7.10"/>
                    <measurement group_id="O4" value="3.25" spread="8.74"/>
                    <measurement group_id="O5" value="0.85" spread="7.790"/>
                    <measurement group_id="O6" value="3.99" spread="9.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of systolic blood pressure. Null hypothesis of no treatment difference was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model used treatment and country as fixed effects and baseline as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.27</ci_lower_limit>
            <ci_upper_limit>-0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for diastolic blood pressure. The null hypothesis of no treatment difference was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model used treatment and country as fixed effects and baseline as covariate.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-3.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.92</ci_lower_limit>
            <ci_upper_limit>-1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis of systolic blood pressure. Null hypothesis of no treatment difference was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1330</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model used treatment and country as fixed effects and baseline as covariate.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.93</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Analysis for diastolic blood pressure. The null hypothesis of no treatment difference was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3442</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model used treatment and country as fixed effects and baseline as covariate.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.27</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For seated systolic blood pressure the null hypothesis of no treatment difference was tested</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model used treatment and country as fixed effects and baseline as covariate.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-3.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.24</ci_lower_limit>
            <ci_upper_limit>-1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>For seated diastolic blood pressure the null hypothesis of no treatment difference was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model used treatment and country as fixed effects and baseline as covariate.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.65</ci_lower_limit>
            <ci_upper_limit>-0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3</title>
        <description>Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort C.</description>
        <time_frame>Week 3 (period 3 baseline) to week 5 (end of Period 3)</time_frame>
        <population>Intent to treat population defined as subjects who finished Period 2, had the end of Period 2 seated systolic or diastolic blood pressure measurement, took the Period 3 study medication for at least one week, and had the end of Period 3 seated systolic or diastolic blood pressure measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort C: OM Period 3</title>
            <description>Cohort C consisted of children from 1 to 5 years of age. There were no racial restrictions. This group continued on its Period 2 olmesartan dose of 0.3 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>Cohort C: Placebo Period 3</title>
            <description>Cohort C consisted of children from 1 to 5 years of age. There were no racial restrictions. This group was switched from its Period 2 olmesartan dose of 0.3 mg/kg to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3</title>
          <description>Mean change from period 3 baseline (completion of the dose adjustment period and prior to starting the treatment of period 3) to the end of period 3 (double-blind placebo-controlled period) in seated systolic and diastolic blood pressure readings for Cohort C.</description>
          <population>Intent to treat population defined as subjects who finished Period 2, had the end of Period 2 seated systolic or diastolic blood pressure measurement, took the Period 3 study medication for at least one week, and had the end of Period 3 seated systolic or diastolic blood pressure measurement.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seated Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="8.994"/>
                    <measurement group_id="O2" value="4.95" spread="8.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seated Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="8.556"/>
                    <measurement group_id="O2" value="3.77" spread="7.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For seated systolic blood pressure the null hypothesis of no treatment difference was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2113</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model used treatment and country as fixed effects and baseline as covariate.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.29</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For seated diastolic blood pressure the null hypothesis of no treatment difference was tested.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1496</p_value>
            <method>ANCOVA</method>
            <method_desc>The ANCOVA model used treatment and country as fixed effects and baseline as covariate.</method_desc>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.92</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)</title>
        <description>Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.</description>
        <time_frame>Day 0 to week 51 (end of study)</time_frame>
        <population>Intent to treat population includes participants with at least one visit in Period 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: Period 4 Open-label OM</title>
            <description>All members of Cohort A (6-16 years old with a limit on the number of Black participants) were given 10 mg to 40 mg of olmesartan (OM) administered as oral suspension or tablets depending on participant weight and response in the open-label Period 4. Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: Period 4 Open-label OM</title>
            <description>All members of Cohort B (6-16 years old comprised exclusively of Black participants) were given 10 mg to 40 mg of olmesartan (OM) administered as oral suspension or tablets depending on participant weight and response in the open-label Period 4. Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
          </group>
          <group group_id="O3">
            <title>Cohorts A + B: Period 4 Open-label OM</title>
            <description>All members of Cohorts A + B (6-16 years old) were given 10 mg to 40 mg of olmesartan (OM) administered as oral suspension or tablets depending on participant weight and response in the open-label Period 4. Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)</title>
          <description>Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort A, Cohort B and Cohorts A+B combined.</description>
          <population>Intent to treat population includes participants with at least one visit in Period 4.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="9.75"/>
                    <measurement group_id="O2" value="-7.7" spread="12.71"/>
                    <measurement group_id="O3" value="-9.7" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="9.31"/>
                    <measurement group_id="O2" value="-5.1" spread="9.45"/>
                    <measurement group_id="O3" value="-6.6" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)</title>
        <description>Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort C.</description>
        <time_frame>Day 0 to week 51 week (end of study)</time_frame>
        <population>57=the number of participants who received medication in Period 4</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort C: OM (Olmesartan Medoxomil)</title>
            <description>Cohort C (1-5 years old) was given olmesartan medoxomil (OM) 0.3 mg/kg in Period 2 (open-label period) and a subgroup of Cohort C was given that dose of OM during Period 3 (double-blind, placebo-controlled period). In Period 4 (open-label period), all of Cohort C received an OM starting dose of 0.3 mg/kg. If hypertension was not controlled after two week the dose was doubled. Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)</title>
          <description>Mean change from baseline to the end of the open label Period 4 in seated systolic and diastolic blood pressure readings for Cohort C.</description>
          <population>57=the number of participants who received medication in Period 4</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected starting with the signing of the informed consent form and continuing through the end of the study (51 weeks)</time_frame>
      <desc>AEs observed by the investigator, or reported by the subject, and any remedial action taken, were recorded in the case report form by the investigator. The nature of each event, time of onset after drug administration, duration, and intensity were documented together with the investigators opinion of the causal relationship to the treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort A: Period 2 High Dose OM</title>
          <description>For Cohort A (participants 6-16 years old), olmesartan medoxomil suspension (OM) providing 20 mg or 40 mg, depending on weight.</description>
        </group>
        <group group_id="E2">
          <title>Cohort A: Period 2 Low Dose OM</title>
          <description>For Cohort A (participants 6-16 years old), olmesartan medoxomil suspension (OM) providing 2.5 mg or 5 mg, depending on weight.</description>
        </group>
        <group group_id="E3">
          <title>Cohort A: Period 3 OM High Dose Continued</title>
          <description>The 20 mg or 40 mg dose of olmesartan medoxomil suspension (OM) from the previous period was continued.</description>
        </group>
        <group group_id="E4">
          <title>Cohort A: Period 3 Placebo From High Dose</title>
          <description>Placebo was given instead of the previous high dose of olmesartan</description>
        </group>
        <group group_id="E5">
          <title>Cohort A: Period 3 OM Low Dose Continued</title>
          <description>The 2.5 mg or 5 mg dose of olmesartan medoxomil suspension (OM) from the previous period was continued.</description>
        </group>
        <group group_id="E6">
          <title>Cohort A: Period 3 Placebo From Low Dose</title>
          <description>Placebo was given instead of the previous low dose of olmesartan</description>
        </group>
        <group group_id="E7">
          <title>Cohort A: Period 4 Open-label OM</title>
          <description>10 mg to 40 mg of olmesartan (OM) was administered as oral suspension or tablets depending on participant weight and response. Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
        </group>
        <group group_id="E8">
          <title>Cohort B: Period 2 High Dose OM</title>
          <description>For Cohort A (participants 6-16 years old), olmesartan medoxomil suspension (OM) providing 20 mg or 40 mg, depending on weight.</description>
        </group>
        <group group_id="E9">
          <title>Cohort B: Period 2 Low Dose OM</title>
          <description>For Cohort B (participants 6-16 years old), olmesartan medoxomil suspension (OM) providing 2.5 mg or 5 mg, depending on weight.</description>
        </group>
        <group group_id="E10">
          <title>Cohort B: Period 3 OM High Dose Continued</title>
          <description>The 20 mg or 40 mg dose of olmesartan medoxomil suspension (OM) from the previous period was continued.</description>
        </group>
        <group group_id="E11">
          <title>Cohort B: Period 3 Placebo From High Dose</title>
          <description>Placebo was given instead of the previous high dose of olmesartan</description>
        </group>
        <group group_id="E12">
          <title>Cohort B: Period 3 OM Low Dose Continued</title>
          <description>The 2.5 mg or 5 mg dose of olmesartan medoxomil suspension (OM) from the previous period was continued.</description>
        </group>
        <group group_id="E13">
          <title>Cohort B: Period 3 Placebo From Low Dose</title>
          <description>Placebo was given instead of the previous low dose of olmesartan</description>
        </group>
        <group group_id="E14">
          <title>Cohort B: Period 4 Open-label OM</title>
          <description>10 mg to 40 mg of olmesartan (OM) was administered as oral suspension or tablets depending on particpant weight and response. Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
        </group>
        <group group_id="E15">
          <title>Cohort C: Period 2 Open-label OM</title>
          <description>The dose of olmesartan medoxomil suspension (OM) was 0.3 mg/kg for all particpants who were 1 to 5 years of age.</description>
        </group>
        <group group_id="E16">
          <title>Cohort C: Period 3 OM Dose Continued</title>
          <description>The 0.3 mg/kg dose of OM was continued for these participants</description>
        </group>
        <group group_id="E17">
          <title>Cohort C: Period 3 Placebo</title>
          <description>The 0.3 mg/kg dose of olmesartan medoxomil suspension (OM) was discontinued for these participants. They were switched to placebo.</description>
        </group>
        <group group_id="E18">
          <title>Cohort C: Period 4 Open-label OM</title>
          <description>Participants received an olmesartan medoxomil suspension (OM) starting dose of 0.3 mg/kg. If hypertension was not controlled after two week the dose was doubled. Additional antihypertensive drugs (not an angiotensin converting enzyme or angiotensin receptor blocker) were allowed if hypertension was not controlled.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="179"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="104"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Coarctation of the aorta</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Ophthalmoplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anasarca</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abcess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Broncopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Laparoscopy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Hypoproteinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Metabolic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="179"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="128" subjects_at_risk="178"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="56" subjects_at_risk="103"/>
                <counts group_id="E15" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E16" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E17" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="46" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="7" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="178"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="11" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Pseudohyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="178"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="178"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="18" subjects_at_risk="103"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Proteinurea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="178"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E18" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If identified by Daiichi Sankyo Inc.(DSI), any of DSI's confidential information, as defined to the author, shall be deleted. Nothing in our site agreement shall be taken as giving DSI any right of editorial control over any publication prepared by the study site.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Kessler, Senior Director Regulatory Operations</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>732-590-5032</phone>
      <email>hmkessler@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

